Latest On Biogen Inc (BIIB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 08:33 EST | News | Elon Musk's Neuralink gets FDA nod to start human trial of brain implant | N/A |  |
| 2023-05-18 17:55 EST | News | Sen. Wyden presses HHS, CMS on access to new Alzheimer's therapies | N/A | |
| 2023-05-16 11:04 EST | News | Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal | N/A | |
| 2023-05-14 15:55 EST | News | Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study | N/A | |
| 2023-05-03 21:37 EST | News | Biogen wins EU exclusivity for Tecfidera until 2025 | N/A | |
About Biogen Inc (BIIB):
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymp read more...homa; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
General
- Name Biogen Inc
- Symbol BIIB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 9,100
- Last Split Factor3:1
- Last Split Date2001-01-18
- Fiscal Year EndDecember
- IPO Date1991-09-16
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.biogen.com
Valuation
- Trailing PE 10.58
- Forward PE 14.01
- Price/Sales (Trailing 12 Mt.) 3.17
- Price/Book (Most Recent Quarter) 3.76
- Enterprise Value Revenue 3.38
- Enterprise Value EBITDA 7.93
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $18.45
- Next Year EPS Estimate $20.17
- Next Quarter EPS Estimate $6.14
- Profit Margin 30%
- Operating Margin 35%
- Return on Assets 11%
- Return on Equity 34%
- Revenue 13.44 billion
- Earnings Per Share $24.80
- Revenue Per Share $83.56
- Gross Profit 11.64 billion
- Quarterly Earnings Growth -22.3%
Highlights
- Market Capitalization 39.95 billion
- EBITDA 5.11 billion
- PE Ratio 25.74
- PEG Ratio 6.24
- Analyst Target Price $289.76
- Book Value Per Share $70.21
Share Statistics
- Shares Outstanding 153.88 million
- Shares Float 151.3 million
- % Held by Insiders 63%
- % Held by Institutions 87.89%
- Shares Short 3.57 million
- Shares Short Prior Month 3.42 million
- Short Ratio 2.6
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 0.42
- 52 Week High $350.24
- 52 Week Low $223.25
- 50 Day Moving Average 271.77
- 200 Day Moving Average 265.59
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ESG Rating
Biogen Inc (BIIB) Dividend Calendar:
Biogen Inc (BIIB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Biogen Inc (BIIB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Biogen Inc (BIIB) Chart:
Biogen Inc (BIIB) News:
Below you will find a list of latest news for Biogen Inc (BIIB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Biogen Inc (BIIB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest BIIB Trades:
Biogen Inc (BIIB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-21 | 8-K (Current report) | |
| 2020-10-21 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-28 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-28 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-20 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 8-K (Current report) | |
| 2020-07-22 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-22 | 8-K (Current report) | |
| 2020-07-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 8-K (Current report) | |
| 2020-06-18 | 8-K (Current report) | |
| 2020-06-05 | 8-K (Current report) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
Biogen Inc (BIIB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biogen Inc (BIIB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 63%
Institutional Ownership: 8789%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | Alfred Sandrock | EVP, Research & Development | Sell | 1,500.00 | 350.00 | 525,000.00 | 13,066.21 | |
| 2020-07-31 | Ginger Gregory | EVP, Human Resources | Buy | 212.00 | 4,786.36 | | ||
| 2020-06-03 | ALEXANDER J DENNER | Director | Buy | 890.00 | 12,954.00 | | ||
| 2020-06-03 | Richard Mulligan | Director | Buy | 890.00 | 12,954.00 | | ||
| 2020-06-03 | NANCY LEAMING | Director | Buy | 890.00 | 12,988.00 | | ||
| 2020-06-03 | STEPHEN A SHERWIN | Director | Buy | 890.00 | 16,328.00 | | ||
| 2020-06-03 | Eric K Rowinsky | Director | Buy | 890.00 | 17,069.00 | | ||
| 2020-06-03 | Jesus B Mantas | Director | Buy | 890.00 | 2,045.00 | | ||
| 2020-06-03 | WILLIAM A HAWKINS | Director | Buy | 890.00 | 2,045.00 | | ||
| 2020-06-03 | ROBERT W PANGIA | Director | Buy | 890.00 | 20,632.00 | | ||
| 2020-06-03 | CAROLINE DORSA | Director | Buy | 890.00 | 21,097.00 | | ||
| 2020-06-03 | STELIOS PAPADOPOULOS | Director | Buy | 1,470.00 | 6,565.00 | | ||
| 2020-06-03 | Brian S Posner | Director | Buy | 890.00 | 7,885.00 | | ||
| 2020-03-11 | STEPHEN A SHERWIN | Director | Sell | 2,164.00 | 295.22 | 638,845.26 | 14,353.00 | |
| 2020-03-11 | STEPHEN A SHERWIN | Director | Sell | 270.00 | 295.29 | 79,728.30 | 15,438.00 | |
| 2020-03-11 | STEPHEN A SHERWIN | Director | Buy | 1,355.00 | 58.46 | 79,213.30 | 15,708.00 | |
| 2020-03-11 | STEPHEN A SHERWIN | Director | Buy | 10,923.00 | 58.46 | 638,558.58 | 16,517.00 | |
| 2020-02-15 | Alfred Sandrock | EVP, Research & Development | Buy | 1,213.00 | 15,019.25 | | ||
| 2020-02-15 | Alphonse Galdes | EVP Pharmaceutical Oper & Tech | Buy | 441.00 | 2,672.26 | | ||
| 2020-02-15 | Michel Vounatsos | Chief Executive Officer | Buy | 4,847.00 | 33,775.32 | |